Saturday, 10 October 2026European Markets

GYLDENDAL Stock Over 9% Down So Far Today

Loading stream...

(VIANEWS) - Shares of GYLDENDAL (Oslo Børs Benchmark Index_GI: GYL.OL) slid 9.91% to kr500.00 at 11:38 EST on Thursday, after five successive sessions in a row of losses. Oslo Børs Benchmark Index_GI is falling 1.18% to kr1,213.09, following the last session's downward trend. This seems, up until now, an all-around down trend trading session today.

About GYLDENDAL

Gyldendal ASA, through its subsidiaries publishes and sells books in Norway. It also operates 143 bookstores and an online bookstore. In addition, it publishes dictionaries and encyclopedias; and provides logistics and reporting services to the book industry. The company was founded in 1925 and is based in Oslo, Norway. Gyldendal ASA is a subsidiary of Erik Must AS.

Earnings Per Share

As for profitability, GYLDENDAL has a trailing twelve months EPS of kr8.82.

PE Ratio

GYLDENDAL has a trailing twelve months price to earnings ratio of 56.69. Meaning, the purchaser of the share is investing kr56.69 for every norwegian krone of annual earnings.

Volume

Today's last reported volume for GYLDENDAL is 2 which is 66.66% below its average volume of 6.

More news about GYLDENDAL (GYL.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Agentic Enterprise Software Consolidates: Big Platforms Push Autonomy While Startups Get Absorbed
Enterprise software is shifting toward autonomous, AI-agent-driven products. SAP (Autonomous Enterprise, Joule), Meta (a new Enterprise Platform led by ex-MongoDB CEO Chirantan Desai) and UiPath (raised guidance) are pushing from the top. Meanwhile AI-security and governance startups are being acquired (Fortinet–Virtue AI, Harvey–Guardrails AI, Tiny–Oso Cloud) and seed-stage agent companies keep raising capital (Dextr, Latitude, Groq). Investors such as Norwest's Sean Jacobsohn see finance and ERP back-office software as the easier area to disrupt. Trust and enforced governance are treated as preconditions for regulated sectors like finance, and AI is judged unreliable for calculations.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,366 source documents archived
Query this data → isubstrate.com